फार्माकोजेनोमिक्स और फार्माकोप्रोटिओमिक्स जर्नल

अमूर्त

Profiles of Liver Function Tests among Type 2 Diabetic Patients Who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospitals

 Desaleng Dango, Melaku Umeta, Solomon Genet, Menakath Menon, Tedla Kebede and Jemal Beker

Background: Diabetes Mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia with disturbances of carbohydrates, fat and protein metabolism resulting from insufficient insulin secretion, defects in insulin secretion, insulin action, or both. Individuals with type 2 diabetes have a higher incidence of liver function abnormalities. The objective of this study was to investigate profile of liver function tests among type 2 diabetic patients who are receiving different anti-diabetic drugs attending Tikur Anbessa Specialized Hospital.

Methods: Hospital based cross-sectional study was conducted on 70 type 2 diabetic patients who are receiving different anti-diabetic drugs and 35 type 2 diabetic patients who do not receive any medication were recruited for this study. The blood was taken at the fasting period and liver enzymes, Total Protein (TP), Albumin (AL), Total Bilirubin (TB), Fasting Blood Sugar (FBS), lipid profiles and Body Mass Index (BMI) were carried out in all patients and control group following the standard procedures.

Results: Mean values of Alkaline Phosphatase (ALP), Albumin (AL), TP and FBS were significantly higher in type 2 diabetic patients receiving different anti-diabetic drugs than in control group. In contrast, mean value of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) among study group were lower than control group. Mean values of TC and LDL were lower in study group than in the control group. The mean value differences between the study group and control of TB, TG and HDL were statistically not significant. There are no significant differences of liver enzymes, TP, AL, TB, and lipid profiles in different patients who were on different anti-diabetic drugs. But mean value of liver enzymes and lipid profiles were slightly lowered in patients receiving mono therapy of insulin and metformin than insulin plus metformin, whereas BMI and FBS were lowered in their combination therapy receiving group. Similarly mean value of FBS, ALT, TC, HDL, LDL and lipid profiles were lowered in patients receiving mono therapy of glibenclamide and metformin than glibenclamide plus metformin combination therapy receiving group, while BMI and TB were increased in patients receiving mono therapy of metformin and glibenclamide.

Conclusion and recommendation: The anti-diabetic drugs were found to have an effect in lowering liver enzymes and lipid profiles in type 2 diabetic patients. The different biochemical parameters tested were more or less similar in different groups of individuals who were on different anti-diabetic drugs of mono therapy or combination therapy.